144876-36-8 Usage
Description
Imidazo[1,2-a]pyridine-2-carboxaldehyde is an organic compound with the molecular formula C8H6N2O. It is a heterocyclic compound featuring a pyridine ring fused with an imidazole ring, and it has a formyl group (-CHO) attached to the second position of the pyridine ring. Imidazo[1,2-a]pyridine-2-carboxaldehyde serves as an important intermediate in the synthesis of various pharmaceuticals and chemical compounds due to its unique structure and reactivity.
Uses
Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridine-2-carboxaldehyde is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential applications in treating different diseases, including cancer, inflammation, and neurological disorders.
Used in Chemical Synthesis:
Imidazo[1,2-a]pyridine-2-carboxaldehyde is used as a building block in the synthesis of complex organic molecules. Its reactivity and structural diversity make it a valuable compound for creating novel chemical entities with potential applications in various industries, such as materials science, agrochemicals, and specialty chemicals.
Used in Research and Development:
Imidazo[1,2-a]pyridine-2-carboxaldehyde is utilized in research and development for the exploration of new chemical reactions and the development of innovative synthetic methods. Its unique properties and reactivity enable chemists to study new reaction mechanisms and develop more efficient and selective synthetic routes to target molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 144876-36-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,4,8,7 and 6 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 144876-36:
(8*1)+(7*4)+(6*4)+(5*8)+(4*7)+(3*6)+(2*3)+(1*6)=158
158 % 10 = 8
So 144876-36-8 is a valid CAS Registry Number.
InChI:InChI=1/C8H6N2O/c11-4-6-2-1-3-7-8(6)10-5-9-7/h1-5H,(H,9,10)
144876-36-8Relevant articles and documents
BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS
-
, (2020/10/21)
The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists
Hansen, Martin,Jacobsen, Stine Engesgaard,Plunkett, Shane,Liebscher, Gudrun Eckhard,McCorvy, John D.,Br?uner-Osborne, Hans,Kristensen, Jesper Langgaard
, p. 3933 - 3937 (2015/01/30)
N-Benzyl substitution of phenethylamine 5-HT2A receptor agonists has dramatic effects on binding affinity, receptor selectivity and agonist activity. In this paper we examine how affinity for the 5-HT2A/2C receptors are influenced by N-benzyl substitution of 4-bromo-2,5-dimethoxyphenethylamine derivatives. Special attention is given to the 2′ and 3′-position of the N-benzyl as such compounds are known to be very potent. We found that substitutions in these positions are generally well tolerated. The 2′-position was further examined using a range of substituents to probe the hydrogen bonding requirements for optimal affinity and selectivity, and it was found that small changes in the ligands in this area had a profound effect on their affinities. Furthermore, two ligands that lack a 2′-benzyl substituent were also found to have high affinity contradicting previous held notions. Several high-affinity ligands were identified and assayed for functional activity at the 5-HT2A and 5-HT2C receptor, and they were generally found to be less efficacious agonists than previously reported N-benzyl phenethylamines.
